Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Unity Biotechnology, Inc. (UBX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
08/08/2023 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., August 8, 2023 --"
05/09/2023 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., May 9, 2023 --"
04/24/2023 8-K Quarterly results
03/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline 52% of UBX1325-treated patients did not require anti-VEGF treatment through 24 weeks Company to share 48-week BEHOLD DME data in April and intends to initiate Phase 2b study in DME in second half of 2023 UNITY to host investor call today, March 27, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., March 27, 2023",
"4 0 2 4 8 12 16 20 24 28 32 36 40 44 48"
03/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 2 to Sales Agreement, by and between Unity Biotechnology, Inc. and Cowen and Company, LLC",
"Amendment No. 2 to Sales Agreement, by and between Unity Biotechnology, Inc. and Cowen and Company, LLC"
03/15/2023 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., March 15, 2023 --"
11/08/2022 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates - Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months - - 16-Week Data from Phase 2 ENVISION Study in wet Age-Related Macular Degeneration Expected in First Quarter of 2023 - - As of September 30, 2022, UNITY had approximately $103.9 million in cash, cash equivalents and marketable securities, providing runway into the first quarter of 2024 - SOUTH SAN FRANCISCO, Calif., November 8, 2022 --"
11/01/2022 8-K Quarterly results
10/19/2022 8-K Quarterly results
08/22/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among Unity Biotechnology, Inc. and SVB Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the underwriters named therein",
"Form of Warrant",
"Opinion of Latham & Watkins LLP",
"UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering"
08/19/2022 8-K Quarterly results
08/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema",
"Presentation of Unity Biotechnology, Inc."
08/12/2022 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates"
07/05/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/15/2022 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates"
02/03/2022 8-K Quarterly results
12/20/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho Program"
12/15/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "UBX1325 Phase 2 study in DME currently enrolling, with additional Phase 2 study in AMD planned for 1H22 - UNITY to present at invitation-only Eyecelerator innovation conference at AAO"
09/29/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Latham & Watkins LLP",
"Opinion of Latham & Watkins LLP",
"Purchase Agreement, by and between the Company and Lincoln Park",
"Registration Rights Agreement, by and between the Company and Lincoln Park"
08/10/2021 8-K Quarterly results
Docs: "UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema and wet age-related macular degeneration - Results from Phase 1study of UBX1325 in additional patients with wet AMD expected by end of year - UBX1325 Phase 2a proof-of-concept study enrolling patients with DME; data expected first half of 2022"
07/06/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease Improvement in Visual Acuity and Central Subfield Thickness observed in diabetic",
"Presentation of UNITY Biotechnology, Inc."
06/24/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
12/14/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O'Neill, M.B., to the Board of Directors"
11/04/2020 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates"
09/24/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy